By Coolcaesar - wikipedia.orgCardiology Cytokinetics’ Aficamten with breakthrough Phase III resultsCalifornia-based Cytokinetics Inc (CYTK) recorded a big jump in Nasdaq prices, at 40.45%, after presenting the results of its Phase III MAPLE-HCM study at the European Society of Cardiology Congress … more ➔
Polpharma Biologics SApartnershipPolpharma Biologics secures distribution of upcoming biosimilarsPolpharma Biologics SA and MS Pharma SA have signed licensing agreements for Polpharma’s vedolizumab (PB016), ocrelizumab (PB018) and guselkumab (PB019) biosimilars in the Middle East and North Africa … more ➔
adobe stock photos - Sundry Photography Licence agreementGenentech inks US$400m IBD deal with OMass TherapeuticsThe US Roche unit Genentech Inc has signed a US$400 million licence deal with British NativeMS specialist OMass Therapeutics Ltd. Under the exclusive collaboration and licence agreement, Genentech intends … more ➔
adobe stock photos - JHVEPhotoAutoimmune diseasesSanofi receives US approval for oral ITP blockbusterSanofi SA has received FDA marketing approval for Wayrilz (rilzabrutinib). Unlike three existing causal treatments for immune thrombocytopenia (ITP), the oral drug inhibits both processes that drive … more ➔
ForbionLicence dealSitalaBio pays US$670m for Fosun inflammation blockerBritish company Sitala Bio Ltd, founded in 2021 by NLRP3 inflammasome expert Matt Cooper, is paying US$670m and giving up to 10% of its shares to Chinese company Shanghai Fosun Pharmaceutical Group Co. … more ➔
Adobe stock photos - JimObesityLilly’s weight loss pill orforglipron meets primary Phase III endpointEli Lilly, the US market leader in the lucrative diabetes and obesity space, is now challenging its competitor Novo Nordisk in the area of oral GLP-1 receptor agonists. Lilly’s orforglipron has met … more ➔
Calluna Pharma A/SClinical trialsCalluna Pharma starts efficacy test with unique IPF antibodyNorway-based Calluna Pharma A/S has initiated patient recruitment in late August for its Phase II AURORA trial investigating safety and efficacy of CAL101, a monoclonal antibody with unique mode of action … more ➔
BioArctic ABNeurodegenerationNovartis secures US$30m+ licence option from BioArcticFollowing the commercial launch of BioArctic AB’s Alzheimer’s antibody lecanemab, the Swedish company has announced a new deal: it will receive an upfront payment of US$30m, granting the Swiss company … more ➔
Esai PharmaDementiaAlzheimer’s antibody Lecanemab launched in the EUSwedish BioArctic AB’s partner Eisai Pharma has started the European roll-out of their Alzheimer’s antibody lecanemab in Austria that will be followed by the German launch on September 1, 2025. more ➔
EFPIAUS-EU trade conflictUS and EU confirm tariff deal on pharmaceuticals, generics largely exemptThe US and EU have confirmed a trade agreement involving US import tariffs of 15% on prescription medicines. Generics manufacturers will face a maximum tariff of 2.5%. more ➔
By Coolcaesar - wikipedia.org
Polpharma Biologics SA
adobe stock photos - Sundry Photography 
adobe stock photos - JHVEPhoto
Forbion
Adobe stock photos - Jim
Calluna Pharma A/S
BioArctic AB
Esai Pharma
EFPIA